Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study (Q39039468)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2015

Language	Label	Description	Also known as
English	Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study	scientific article published on April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sub-Saharan Africa

0 references

1 reference

based on heuristic

inferred from title

Jürgen Burhenne

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Wondwossen Amogne

3

object named as

Wondwossen Amogne

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

object named as

Eyasu Makonnen

2

0 references

object named as

Eleni Aklillu

8

0 references

object named as

Getnet Yimer

4

0 references

Leif Bertilsson

6

object named as

Leif Bertilsson

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1

object named as

Abiy Habtewold

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Getachew Aderaye

5

object named as

Getachew Aderaye

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

1 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Pharmacogenomics

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1047-1064

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Efavirenz: a decade of clinical experience in the treatment of HIV.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.35

21 January 2018

Identifiers

10.2217/PGS.15.35

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39039468&oldid=2192625221"